<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02262611</url>
  </required_header>
  <id_info>
    <org_study_id>502.428</org_study_id>
    <secondary_id>502.429, 502.430, 502.431</secondary_id>
    <nct_id>NCT02262611</nct_id>
  </id_info>
  <brief_title>Post Marketing Surveillance Study in Rehabilitation Clinics (Cardio, Nephro, Diabetes, Pulmo)</brief_title>
  <official_title>Post Marketing Surveillance Study in Rehabilitation Clinics (Cardio, Nephro, Diabetes, Pulmo)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to obtain long-term data on effects, safety and tolerability in routine medical
      practice and to investigate the potential of telmisartan to prevent secondary organ damage
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with abnormal changes in laboratory parameters</measure>
    <time_frame>up to 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with clinically significant changes in vital signs</measure>
    <time_frame>up to 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in systolic blood pressure</measure>
    <time_frame>up to 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in diastolic blood pressure</measure>
    <time_frame>up to 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global assessment of efficacy by investigator on a 4-point scale</measure>
    <time_frame>2 weeks, after 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of tolerability by investigator on a 4-point scale</measure>
    <time_frame>2 weeks, after 1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">266</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Hypertension patients - Pneumology</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypertension patients - Cardiology</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypertension patients - Nephrology</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypertension patients - Diabetology</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Micardis速</intervention_name>
    <arm_group_label>Hypertension patients - Pneumology</arm_group_label>
    <arm_group_label>Hypertension patients - Cardiology</arm_group_label>
    <arm_group_label>Hypertension patients - Nephrology</arm_group_label>
    <arm_group_label>Hypertension patients - Diabetology</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MicardisPlus速</intervention_name>
    <arm_group_label>Hypertension patients - Pneumology</arm_group_label>
    <arm_group_label>Hypertension patients - Cardiology</arm_group_label>
    <arm_group_label>Hypertension patients - Nephrology</arm_group_label>
    <arm_group_label>Hypertension patients - Diabetology</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with hypertension recruited at hospitals in Germany specialized in cardiology,
        nephrology, diabetology and pneumology
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients of both gender aged &gt;=18 admitted to a hospital due to insufficiently
             controlled essential hypertension.

        No additional selection criteria have to be considered. Treatment was at the discretion of
        the physician following the summary of product information for Micardis速 and MicardisPlus速

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2014</study_first_submitted>
  <study_first_submitted_qc>October 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2014</study_first_posted>
  <last_update_submitted>October 10, 2014</last_update_submitted>
  <last_update_submitted_qc>October 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Telmisartan, hydrochlorothiazide drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

